Barclays Forecasts Strong Price Appreciation for Zoetis (NYSE:ZTS) Stock

Zoetis (NYSE:ZTS) had its price target hoisted by investment analysts at Barclays from $242.00 to $244.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 54.89% from the company’s current price.

ZTS has been the subject of a number of other research reports. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Piper Sandler reduced their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Price Performance

Shares of ZTS opened at $157.54 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a 50 day simple moving average of $168.51 and a 200 day simple moving average of $178.81. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a market capitalization of $71.07 billion, a PE ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Sell-side analysts predict that Zoetis will post 5.9 EPS for the current fiscal year.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zoetis

Large investors have recently added to or reduced their stakes in the business. Darwin Wealth Management LLC bought a new stake in Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services acquired a new position in Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the 3rd quarter valued at $33,000. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.